A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study

BACKGROUND: Activation of the mitogen activated protein kinase pathway plays a pivotal role in cell proliferation and is frequently activated in endometrial cancer. We sought to evaluate the efficacy/safety of selumetinib, a selective MEK-1/2 inhibitor in women with recurrent endometrial cancer. MET...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Gynecol Oncol
Главные авторы: Coleman, Robert L., Sill, Michael W., Thaker, Premal H., Bender, David P., Street, Daron, McGuire, William, Johnston, Carolyn M., Rotmensch, Jacob
Формат: Artigo
Язык:Inglês
Опубликовано: 2015
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4469526/
https://ncbi.nlm.nih.gov/pubmed/25887099
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2015.04.005
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы